文献速递甲状腺疾病

甲状腺髓样癌细胞CD133表达可识别预后不良患者

CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该研究纳入74例甲状腺髓样癌(MTC)患者,分析CD133免疫组化表达与临床病理特征及疾病进展的关系,并探索其调控机制。结果显示CD133表达与不良临床病理特征相关,且在多变量分析中是预后不良的独立因素(风险比=16.6,P=0.001)。作者认为CD133表达可能有助于识别预后不良的MTC患者。

要点

  • CD133免疫组化表达与MTC不良临床病理特征相关,并预测疾病进展时间缩短。
  • 多变量分析中CD133表达是预后不良的独立因素(风险比=16.6,P=0.001)。
  • hsa-miR-30a-5p被定义为CD133表达调控因子,其在侵袭性MTC中下调。

核心结论

  • 作者认为CD133表达可能是识别预后不良MTC患者的有用工具,这些患者可能从更广泛的原发手术治疗和随访中获益。

研究设计与样本

  • 研究汇编了74例甲状腺髓样癌(MTC)及其相关临床数据,并对RET和RAS原癌基因突变进行了特征分析。

主要发现

  • CD133免疫组化表达与不良临床病理特征相关,并预测疾病进展时间缩短,即使仅分析RET突变病例也是如此(对数秩检验P < 0.003)。
  • 无进展生存的单变量分析显示,CD133表达和瘤周血管内瘤栓是最显著的预后协变量,其他因素包括年龄、性别和预后分期。
  • 多变量分析确定CD133表达和瘤周血管内瘤栓均为预后不良的独立因素(风险比=16.6和2;P=0.001和0.010)。
  • hsa-miR-30a-5p被定义为CD133表达调控因子,其在侵袭性MTC中下调;在MZ-CRC-1(RETM918T)细胞中异位表达hsa-miR-30a-5p显著降低了CD133 mRNA表达。

临床怎么用

  • 作者认为CD133表达可能有助于识别预后不良的MTC患者,这些患者可能从更广泛的原发手术治疗和随访中获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The identification of markers able to determine medullary thyroid cancer (MTC) patients at high-risk of disease progression is critical to improve their clinical management and outcome. Previous studies have suggested that expression of the stem cell marker CD133 is associated with MTC aggressiveness. OBJECTIVE: To evaluate CD133 impact on disease progression in MTC and explore the regulatory mechanisms leading to the upregulation of this protein in aggressive tumors. PATIENTS: We compiled a series of 74 MTCs with associated clinical data and characterized them for mutations in RET and RAS proto-oncogenes, presumed to be related with disease clinical behavior. RESULTS: We found that CD133 immunohistochemical expression was associated with adverse clinicopathological features and predicted a reduction in time to disease progression even when only RET-mutated cases were considered in the analysis (log-rank test P < 0.003). Univariate analysis for progression-free survival revealed CD133 expression and presence of tumor emboli in peritumoral blood vessels as the most significant prognostic covariates among others such as age, gender, and prognostic stage. Multivariate analysis identified both variables as independent factors of poor prognosis (hazard ratio = 16.6 and 2; P = 0.001 and 0.010, respectively). Finally, we defined hsa-miR-30a-5p, a miRNA downregulated in aggressive MTCs, as a CD133 expression regulator. Ectopic expression of hsa-miR-30a-5p in MZ-CRC-1 (RETM918T) cells significantly reduced CD133 mRNA expression. CONCLUSIONS: Our results suggest that CD133 expression may be a useful tool to identify MTC patients with poor prognosis, who may benefit from a more extensive primary surgical management and follow-up.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Cordero-Barreal A, Caleiras E, López de Maturana E, et al. CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis. J Clin Endocrinol Metab. 2020. PMID: 32791518. doi:10.1210/clinem/dgaa527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。